Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology

类有机物 医学 肿瘤科 病理 内科学 医学物理学 心理学 神经科学
作者
Anna Golebiewska,Ann‐Christin Hau,Anaïs Oudin,Daniel Stieber,Yahaya Abubakar Yabo,Virginie Baus,Vanessa Barthelemy,Eliane Klein,Sébastien Bougnaud,Olivier Keunen,May Wantz,Alessandro Michelucci,Virginie Neirinckx,Arnaud Muller,Tony Kaoma,Petr V. Nazarov,Francisco J Azuaje,Alfonso De Falco,Ben Flies,Lorraine Richart
出处
期刊:Acta Neuropathologica [Springer Science+Business Media]
卷期号:140 (6): 919-949 被引量:168
标识
DOI:10.1007/s00401-020-02226-7
摘要

Patient-based cancer models are essential tools for studying tumor biology and for the assessment of drug responses in a translational context. We report the establishment a large cohort of unique organoids and patient-derived orthotopic xenografts (PDOX) of various glioma subtypes, including gliomas with mutations in IDH1, and paired longitudinal PDOX from primary and recurrent tumors of the same patient. We show that glioma PDOXs enable long-term propagation of patient tumors and represent clinically relevant patient avatars that retain histopathological, genetic, epigenetic, and transcriptomic features of parental tumors. We find no evidence of mouse-specific clonal evolution in glioma PDOXs. Our cohort captures individual molecular genotypes for precision medicine including mutations in IDH1, ATRX, TP53, MDM2/4, amplification of EGFR, PDGFRA, MET, CDK4/6, MDM2/4, and deletion of CDKN2A/B, PTCH, and PTEN. Matched longitudinal PDOX recapitulate the limited genetic evolution of gliomas observed in patients following treatment. At the histological level, we observe increased vascularization in the rat host as compared to mice. PDOX-derived standardized glioma organoids are amenable to high-throughput drug screens that can be validated in mice. We show clinically relevant responses to temozolomide (TMZ) and to targeted treatments, such as EGFR and CDK4/6 inhibitors in (epi)genetically defined subgroups, according to MGMT promoter and EGFR/CDK status, respectively. Dianhydrogalactitol (VAL-083), a promising bifunctional alkylating agent in the current clinical trial, displayed high therapeutic efficacy, and was able to overcome TMZ resistance in glioblastoma. Our work underscores the clinical relevance of glioma organoids and PDOX models for translational research and personalized treatment studies and represents a unique publicly available resource for precision oncology.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
宥沐发布了新的文献求助10
刚刚
李健的应助被zz采纳,获得10
刚刚
三月烟雨完成签到,获得积分10
1秒前
1秒前
null的应助被科研通管家采纳,获得10
1秒前
打打的应助被科研通管家采纳,获得10
1秒前
机智雪糕完成签到,获得积分10
1秒前
科研通AI2S的应助被科研通管家采纳,获得10
1秒前
风吹麦浪的应助被科研通管家采纳,获得20
1秒前
369ninja的应助被tomatoGG采纳,获得10
1秒前
null的应助被科研通管家采纳,获得10
1秒前
1秒前
null的应助被科研通管家采纳,获得10
2秒前
阿盛完成签到,获得积分10
2秒前
田様的应助被科研通管家采纳,获得10
2秒前
尧九完成签到,获得积分10
2秒前
2秒前
2秒前
2秒前
烟花的应助被如愿采纳,获得10
3秒前
lu2025发布了新的文献求助10
3秒前
悠然地八音完成签到,获得积分10
3秒前
likun_42完成签到,获得积分10
3秒前
3秒前
3秒前
香蕉觅云的应助被袁气奶豆采纳,获得10
3秒前
NANO完成签到,获得积分10
3秒前
古田森森完成签到,获得积分10
4秒前
超超兽完成签到,获得积分10
5秒前
北鸢发布了新的文献求助10
5秒前
lzhgoashore完成签到,获得积分10
5秒前
wmy发布了新的文献求助10
6秒前
乐观的幼珊完成签到,获得积分10
6秒前
充电宝的应助被123采纳,获得10
6秒前
坚定的迎波完成签到,获得积分10
6秒前
7秒前
赘婿的应助被鱼骨采纳,获得10
7秒前
穆雨发布了新的文献求助10
7秒前
Elytra驳回了思源的应助
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159542
求助须知:如何正确求助?哪些是违规求助? 9555044
关于积分的说明 21724263
捐赠科研通 7749434
什么是DOI,文献DOI怎么找? 3427246
关于科研通互助平台的介绍 2552263
邀请新用户注册赠送积分活动 2471618